Abstract
Background Mechanical circulatory support (MCS) devices, including veno-arterial extracorporeal membrane oxygenation (VA-ECMO) and Impella, have been widely used for patients with cardiogenic shock (CS). However, hemodynamics with each device and combination therapy is not thoroughly understood. We aimed to elucidate the hemodynamics with MCS using a CS pulsatile flow model.
Methods and Results A pulsatile flow circulation system comprising a ventricle, aortic valve, mitral valve, elastic artery, and venous reservoir was developed. Hemodynamics with Impella CP, VA-ECMO, and a combination of Impella CP and VA-ECMO were assessed based on the pressure and flow under support with each device and the pressure-volume loop of the ventricle model. The self-recirculation with Impella was assessed using particle image velocimetry. The Impella CP device with CS status resulted in increased afterload, leading to an increase in aortic pressure and a decrease in end-diastolic volume and end-diastolic pressure (EDP). VA-ECMO support resulted in increased afterload, leading to a significant increase in aortic pressure with an increase in end-systolic volume and EDP and decreasing venous reservoir pressure. The combination of Impella CP and VA-ECMO led to left ventricular unloading, regardless of increase in afterload. Self-recirculation with Impella CP was observed in a patient with significant aortic insufficiency, leading to reduced hemodynamic support.
Conclusions The Impella system improved hemodynamics with ventricular unloading. Hemodynamic support with Impella and VA-ECMO should be a promising combination for patients with severe CS. Physicians should be alert to the presence of significant aortic insufficiency, leading to self-recirculation with Impella.
What is new?
This is a non-clinical study using a novel experimental pulsatile flow system with venous function that can be used to assess MCS, including Impella and VA-ECMO.
The self-recirculation phenomenon of the Impella device was assessed by a flow visualization method using particle imaging velocimetry.
What are the clinical implications?
The combination of Impella and VA-ECMO led to left ventricular unloading, regardless of the increase in afterload.
VA-ECMO could increase arterial pressure owing to increased LV afterload and alter the direction of the aortic flow (antegrade or retrograde) depending on the flow level with VA-ECMO.
Effective Impella flow was reduced during ventricular diastole when aortic insufficiency was present owing to self-recirculation with the Impella device.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by AMED under Grant Number JP22mk0101179 and in part by the Subsidy Program for the Development of International Standards for the Evaluation of Innovative Medical Devices and Regenerative Medicine Products of the Ministry of Health, Labor and Welfare, Japan. The Impella circulatory support system and VA-ECMO were provided by Abiomed Japan and Senko Medical Instruments.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB review has not been conducted because this study was performed using a pulsatile flow model.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data Availability
We included a statement in the Methods.
